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Correspondence 335anti-chlamydial effect than roxithromycin given for
28 days in our study.
A possible effect of macrolides on PAD depends on
(I) selection of patients with clinically relevant
endovascular infection with C. pneumoniae and (II)
treatment of these patients with an effective regimen.
The relevance of patient selection is often under-
estimated. We selected—in contrast to Vainas et al.—
patients with high antibody titers (IgGR1/128) and a
high clinical activity of peripheral atherosclerosis
(severe impairment of PAD was observed in 65% of
the placebo-treated patients). These features might
indicate endovascular chlamydial disease. In our
study, a significant association between C. pneumoniae
seropositivity and incidence of PAD confirmed the
involvement of C. pneumoniae.3 It is worth noting, that
C. pneumoniae seropositivity was also significantly
related to peripheral arterial events in the study by
Vainas et al.1
It will be subject of further studies to evaluate
whether a high clinical activity of peripheral athero-
sclerosis in presence of high C. pneumoniae antibody
titers is a reliable criterion for patient selection and
whether administration of macrolides during 1
month is an optimum regimen. A further indicator
of endovascular infection with C. pneumoniae might
be elevated concentrations of serum homocysteine.4
In both Vainas’ and our study, C. pneumoniae
antibodies were preferentially associated with ather-
osclerosis of peripheral arteries. Preference of C.
pneumoniae for peripheral arteries is conceivable since
peripheral arteries have a different embryological
origin and a different histological constitution than
coronary and cerebral arteries.5
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We appreciate the interest of Krayenbuehl and
colleagues in our recently published paper1 although
we believe that their conclusions need some re-
consideration.
Despite the promising initial reports suggesting a
favourable effect of antibiotics on coronary events,
recently published randomised clinical trails, enrol-
ling more than 10,000 patients with acute and/or
chronic coronary artery disease, failed to demonstrate
any beneficial effect of prolonged antibiotic treatment
(3 months–1 year) on coronary artery disease
progression.2–4
The assumption that Chlamydia pneumoniae is
preferentially associated with peripheral arterial
disease (PAD) and that antibiotic treatment of
selected PAD-patients may prove effective needs
some careful evaluation. Despite the different devel-
opmental origin of peripheral arteries, early histo-
logical studies have shown that C. pneumoniae DNA
and proteins were ubiquitously present in athero-
sclerotic plaques throughout the body.5 Furthermore,
it is believed that, after a respiratory tract infection, C.
pneumoniae reaches the vasculature through infected
alveolar macrophages.6 To the best of our knowledge,
no regional differences in leucocyte–endothelial
interactions have been reported, so that preferential
homing of infected monocytes to peripheral athero-
sclerotic sites on the basis of different vascularEur J Vasc Endovasc Surg Vol 30, September 2005
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Correspondence336embryological origin is purely speculative. Taking
into account that numerous sero-epidemiological
studies have related C. pneumoniae serology to
coronary artery disease as well as to peripheral
arterial disease, we believe that the results of
coronary antibiotic intervention trials may be
extrapolated to patients with PAD.
Among the currently published antibiotic trials
only two have included patients with peripheral
arterial disease. We included 509 patients in our
SPACE trial,1 treated them for 3 days with azithro-
mycine (nZ257) or placebo (nZ252) and observed
252 events during a average 2-year follow up (131 in
the azithromycine group vs 121 in the placebo group,
PZns). Wiesli et al.7 randomised only 40 patients to
roxitromycin (nZ20) or placebo (nZ20) for 28 days
and observed a significant reduction in number of
patients with severe walking impairment (four
patients in the roxitromycin group vs 13 patients in
the placebo group, PZ0.040) as well as a significant
reduction in number of vascular interventions (5 vs
29 interventions in roxitromycin vs placebo treated
patients, respectively, PZ0.049) during a 2-year
follow-up. However, the number of patients requir-
ing interventions did not differ significantly between
roxitromycin (nZ4) and placebo (nZ9) treated
patients. Furthermore, at 4 years follow-up, the effect
of roxitromycin on walking impairment and number
of interventions had disappeared.8 Considering the
inaccuracy of walking impairment estimation9 as
well as the fact that 29 interventions occurred in nine
patients which may suggest that some of these
interventions could be related to procedural pro-
blems such as thrombotic reocclusions, dissections,
restenosis due to intima hyperplasia, etc., and not
solely to progression of peripheral arterial disease, it
may be conceivable that the reported beneficial effect
of roxitromycin could reflect a type I error due to
small sample size and limited number of observed
events. Therefore, we do not believe that the currently
available evidence warrants antibiotic prophylaxis in
(selected) patients with PAD.
Nevertheless, Krayenbuehl and colleagues raise a
couple of critical issues. Firstly, a methodological
limitation of all C. pneumoniae related cardiovascular
studies is the inability to select patients with clinically
relevant (vascular) infection. C. pneumoniae IgA or
IgG antibody titers are not related to presence of C.
pneumoniae in vascular tissue. Therefore, despite the
numerous sero-epidemiological reports, no consen-
sus has been reached regarding the serological
detection of chronic active or persistent vascular C.
pneumoniae infection.10 Finally, effective treatment of
chronic (vascular) C. pneumoniae infection may beEur J Vasc Endovasc Surg Vol 30, September 2005more troublesome than initially anticipated. Recent
in vitro evidence suggests that C. pneumoniae carried
within macrophages is refractory to anti-chlamydial
antibiotics11 and that even prolonged antibiotic
treatment fails to completely eliminate C. pneumoniae
from infected epithelial cells.12 In light of these data it
is not surprising that the prolonged treatment
strategies employed in the recently published mega
trials have not resulted in a significant reduction of
cardiovascular events. In animal models, the C.
pneumoniae related progression of atherosclerosis
can only be prevented by antibiotics when they are
administered within 5 days of inoculation of the
animals.13 Considering the fact that the majority of
human C. pneumoniae respiratory tract infections
remain clinically unnoticed and that C. pneumoniae
antibody titers already rise during early childhood,
this may imply that antibiotics may only contribute to
cardiovascular disease prevention when adminis-
tered early in life as part of a primary preventive
strategy.
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